Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.

Begum, P; Cui, W; Popat, S

dc.contributor.author	Begum, P
dc.contributor.author	Cui, W
dc.contributor.author	Popat, S
dc.coverage.spatial	United States
dc.date.accessioned	2022-09-14T08:53:27Z
dc.date.available	2022-09-14T08:53:27Z
dc.date.issued	2022-09-01
dc.identifier	100376
dc.identifier	S2666-3643(22)00100-X
dc.identifier.citation	JTO Clinical and Research Reports, 2022, 3 (9), pp. 100376 -
dc.identifier.issn	2666-3643
dc.identifier.uri	https://repository.icr.ac.uk/handle/internal/5470
dc.identifier.eissn	2666-3643
dc.identifier.eissn	2666-3643
dc.identifier.doi	10.1016/j.jtocrr.2022.100376
dc.description.abstract	gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
dc.format	Electronic-eCollection
dc.format.extent	100376 -
dc.language	eng
dc.language.iso	eng
dc.publisher	ELSEVIER
dc.relation.ispartof	JTO Clinical and Research Reports
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject	Case report
dc.subject	Lorlatinib
dc.subject	Non–small cell lung cancer
dc.subject	ROS1 fusion
dc.subject	ctDNA
dc.title	Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report.
dc.type	Journal Article
dcterms.dateAccepted	2022-06-28
dc.date.updated	2022-09-14T08:52:33Z
rioxxterms.version	VoR
rioxxterms.versionofrecord	10.1016/j.jtocrr.2022.100376
rioxxterms.licenseref.startdate	2022-09-01
rioxxterms.type	Journal Article/Review
pubs.author-url	https://www.ncbi.nlm.nih.gov/pubmed/35966191
pubs.issue	9
pubs.organisational-group	/ICR
pubs.organisational-group	/ICR/Primary Group
pubs.organisational-group	/ICR/Primary Group/ICR Divisions
pubs.organisational-group	/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group	/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group	/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.publication-status	Published online
pubs.publisher-url	http://dx.doi.org/10.1016/j.jtocrr.2022.100376
pubs.volume	3
dc.contributor.icrauthor	Popat, Sanjay
icr.provenance	Deposited by Mr Arek Surman (impersonating Dr Elena Lopez Knowles) on 2022-09-14. Deposit type is initial. No. of files: 1. Files: Crizotinib-Resistant iROS1i G2101A Mutation Associated With Sensitivity to Lorlatinib in iROS1i-Rearranged NSCLC Case Report.pdf